352647-05-3

Upstream product

• 768-95-6 1-adamanthanol 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 1041437-71-1 acetic acid 4-formyl-2-tricyclo[3.3.1.1(0,0)]dec-1-yl phenyl ester 
• 107430-91-1 4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde 
• 1221259-46-6 3-(1-adamantyl)-4-isopropoxybenzaldehyde 
• 932017-92-0 3-(adamantan-1-yl)-4-(benzyloxy)benzaldehyde 
• 932017-96-4 ethyl 3'-(adamantan-1-yl)-4'-benzyloxy-2-(3-(1,3-dioxoisoindolin-2-yl)propoxy)biphenyl-4-carboxylate 
• 932017-91-9 (3E,5E)-6-(3-(adamantan-1-yl)-4-benzyloxyphenyl)-3-(ethoxycarbonyl)hexa-3,5-dienoic acid 
• 932017-89-5 ethyl 3'-(adamantan-1-yl)-4'-benzyloxy-2-hydroxybiphenyl-4-carboxylate 
• 932017-93-1 ethyl (E)-3-(3-(adamantan-1-yl)-4-benzyloxyphenyl)acrylate 
• 932017-94-2 (E)-3-(3-(adamantan-1-yl)-4-benzyloxyphenyl)prop-2-en-1-ol 
• 932017-95-3 (E)-3-(3-(adamantan-1-yl)-4-benzyloxyphenyl)acrylaldehyde 

Relevant academic research and scientific papers

Discovery of new chalone adamantyl arotinoids having RXRα-modulating and anticancer activities

In the present study, a new series of chalcone adamantly arotinoids (chalcone AdArs) derived from RAR antagonist MX781, are synthesized, characterized, and evaluated for the biological activities in vitro. The studies of antiproliferative activity and RXR

Type-I flavone derivative as well as preparation method and application thereof

The invention discloses a type-I flavone derivative as well as a preparation method and application thereof, and relates to a flavone derivate. The preparation method comprises the following steps: sequentially preparing 2,4-dyhydroxy-5-(1-adamantyl)-acet

Ion-exchange-resin-catalyzed adamantylation of phenol derivatives with adamantanols: Developing a clean process for synthesis of 2-(1-adamantyl)-4- bromophenol, A key intermediate of adapalene

A clean process has been developed for the synthesis of 2-adamantylphenol derivatives through adamantylation of substituted phenols with adamantanols catalyzed by commercially available and recyclable ion-exchange sulfonic acid resin in acetic acid.The sole byproduct of the adamantylation reaction,namely water,could be converted into the solvent acetic acid by addition of a slight excess of acetic anhydride during the work-up procedure,making the process waste-free except for regeneration of the ionexchange resin,and facilitating the recycling of the resin catalyst.The ion-exchange sulfonic acid resin catalyst could be readily recycled by filtration and directly reused at least ten times without a significant loss of activity.The key intermediate of adapalene,2-(1-adamantyl)-4-bromophenol,could be produced by means of this waste-free process.

S1P RECEPTORS MODULATORS AND THEIR USE THEREOF

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

New synthetic approach to atypical retinoids: application of a versatile annulation procedure

A new approach to an atypical retinoid is presented. The C15 skeleton was built up by exploiting a step-by-step sequence: the C9 fragment of an intermediate was homologated by reaction with a C4 phosphorane, and then submitted to a benzannulation reaction. The last two carbon atoms were inserted by a Wittig reaction with the C2 phosphorane of ethyl bromoacetate. Manipulation of functional groups was then performed.